Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Synopsys, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.26 (market cap $8.04B), while Synopsys, Inc. trades at $422.2 (market cap $81.55B). The key difference: Synopsys, Inc. is far larger — about 10.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | SNPS | |
|---|---|---|
Market Cap | $8.04B | $81.55B |
Sector | Health | Technology |
52-Week High | $339.75 | $645.59 |
52-Week Low | $241.71 | $380.47 |
Enterprise Value | $7.85B | $89.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Synopsys (SNPS) trades at $433.82, down 2.6% today, with a bearish technical signal from moving averages but oversold short-term RSI at 29.08. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.35 surpassing the $3.15 estimate. Revenue grew to $7.05B in 2025, though net income margin compressed to 8.91%. Valuation multiples remain elevated with a P/E of 99.27 and P/S of 9.16. Recent news highlights Synopsys' strategic pivot toward AI-driven design tools and multiphysics solutions.
Outlook: Analyst consensus is bullish with an average price target of $558.33, implying 29% upside, supported by 24 buy ratings. Risks include integration challenges from the Ansys acquisition, competitive pressures in EDA software, and volatility in semiconductor capex. The stock's high valuation requires sustained execution on AI-related growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
